

# Massimo Dal Monte

## Curriculum Vitae et Studiorum

**Date of birth:** November 6, 1964 (Pontedera, Pisa, Italy).

**Position:** Full Professor of Physiology, Department of Biology, University of Pisa, Italy.

**Contacts:** Prof. Massimo Dal Monte, Department of Biology, University of Pisa, via San Zeno, 31, 56127 Pisa (Italy). Telephone: +390502211426. Email: [massimo.dalmonete@unipi.it](mailto:massimo.dalmonete@unipi.it).

### Education and career

**June 2018-present:** Full Professor of Physiology, Department of Biology, University of Pisa, Italy.

**2014-2018:** Associate Professor of Physiology, Department of Biology, University of Pisa, Italy.

**June 2009-November 2009:** Visiting Fellow, Department of Molecular Genetics, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.

**2006-2014:** Researcher of Physiology, Department of Biology, University of Pisa, Italy.

**2002-2005:** Postdoc fellow, Department of Physiology and Biochemistry, University of Pisa, Italy.

**2001-2002:** Technician (D category), Department of Physiology and Biochemistry, University of Pisa, Italy.

**1998:** Specialization in Biochemistry and Clinical Chemistry, University of Pisa, Italy (magna cum laude)

**1996-2000:** Postdoc fellow, Department of Physiology and Biochemistry, University of Pisa, Italy.

**1996:** PhD in Biochemistry, University of Florence, Italy.

**1992-1996:** PhD student, Department of Physiology and Biochemistry, University of Pisa, Italy.

**1990-1992:** Fellow, Institute of Mutagenesis and Differentiation, CNR, Pisa, Italy.

**1990:** Master degree in Biology, University of Pisa, Italy (magna cum laude).

### Institutional and organizational activities

**2023:** Chair, 73<sup>rd</sup> National Meeting of the Italian Society of Physiology

**November 2020-present:** Director, Department of Biology, University of Pisa

**September 2020-present:** Board Member, Italian Society of Physiology.

**2019-2020:** vice-president of the Bachelor degree in Biotechnology, Department of Biology, University of Pisa, Italy.

**2019-2020:** vice-president of the Master degree in Molecular Biotechnology, Department of Biology, University of Pisa, Italy.

**2018-2020:** Member of the Scientific Committee of Area 05 – Biology, University of Pisa, Italy.

**2015-2020:** Coordinator of International Collaborations, Department of Biology, University of Pisa, Italy.

**2015-2020:** Erasmus+ Coordinator, Department of Biology, University of Pisa, Italy.

**2015-2020:** Chair of the General Physiology Unit, Department of Biology, University of Pisa, Italy.

**2014-2019:** Member of the Animal Welfare Board, University of Pisa, Italy.

**2012-present:** Member of the Board of the Ph.D. program in Molecular Medicine, University of Siena, Italy.

**2012-2019:** Responsible of the Animal Facility, Department of Biology, University of Pisa, Italy.

**2012-2018:** Member of the Scientific Committee of the Library of Natural and Environmental Sciences, Chemistry, Mathematics, Informatics and Physics, University of Pisa, Italy.

**2012-2016:** Member of the Scientific Committee of Area 05 – Biology, University of Pisa, Italy.

**2009-2011:** Member of the Board of the Ph.D. School in Biological and Molecular Sciences, University of Pisa, Italy.

**2009-2011:** Member of the Board of the Ph.D. School in Neurosciences and Endocrine-metabolic Sciences, University of Pisa, Italy.

**2008-2010:** Member of the Scientific Committee of Area 05 – Biology, University of Pisa, Italy.

**2008-2012:** Member of the Scientific Committee of the Library of Natural and Environmental Sciences, University of Pisa, Italy.

**2007-2010:** Member of the Board of Dean's Advisor, Faculty of Sciences, University of Pisa, Italy.

**2010:** Supporting activities in the organization of the commemoration of the centennial anniversary of Moruzzi's birthday.

**2009-2011:** Member of the Board of the Ph.D. School in Basic and Developmental Neurosciences, University of Pisa, Italy.

**2009-2012:** Supporting activities in the organization of the Annual Meeting of Young Researchers in Physiology in Pisa (2009 and 2010) and in Sestri Levante (2011 and 2012).

**2006-2008:** Member of the Scientific Committee of Area 05 – Biology, University of Pisa, Italy.

**2006-present:** Member of the Departmental Council, Department of Biology, University of Pisa, Italy.

**2004:** Supporting activities in the organization of the 55<sup>th</sup> National Congress of the Physiological Society of Italy

### **Teaching activities**

Bachelor degree in Biotechnology, Department of Biology, University of Pisa, Italy: Cell and Systems Physiology.

Master degree in Molecular Biotechnology, Department of Biology, University of Pisa, Italy: Advanced Neurosciences.

Master degree in Biology Applied to Biomedical Sciences, Department of Biology, University of Pisa, Italy: Molecular and Cell Physiology.

Master degree in Molecular and Cell Biology, Department of Biology, University of Pisa, Italy: Animal Experimentation and Alternative Model Systems.

### **Research activities**

Role of neuropeptides in retinal physiology

Molecular mechanisms underlying retinopathy of prematurity

Functional role of the beta adrenergic system: retinopathy of prematurity, retinitis pigmentosa and melanoma

Functional role of beta-3 adrenoceptors as oxygen sensors

Molecular mechanisms underlying diabetic retinopathy

Functional role of the uPAR system in diabetic retinopathy

Molecular mechanisms underlying retinitis pigmentosa

Role of neuroinflammation in retinal diseases

Nutraceuticals in the treatment of retinal diseases

Eye drops based on natural products to treat eye diseases

### **Editorial activities**

**2022:** Guest Editor for the Research Topic of Frontiers in Pharmacology “Novel Therapeutic Approaches for the Treatment of Ocular Disease, Volume II”.

**2022:** Guest Editor for the Special Issue of International Journal of Molecular Sciences “New Drugs in the Treatment of Retinal Diseases”.

**2022-present:** Frontiers in Medicine, Review Editor.

**2021:** Guest Editor for the Special Issue of Biomedicine “Neural and vascular dysfunctions in retinal diseases: mechanisms and treatments”.

**2020-present:** Biomolecules, Editorial Board Member.

**2018-present:** Frontiers in Bioengineering and Biotechnology, Review Editor.

**2018-present:** Frontiers in Molecular Biosciences, Review Editor.

**2018-present:** Frontiers in Pediatrics, Review Editor.

**Ad-hoc reviewer for more than 50 journals including:** Acta Ophthalmologica; American Journal of Pathology; Angiogenesis; British Journal of Pharmacology; Diabetes, Obesity and Metabolism; Experimental Eye Research; Investigative Ophthalmology & Visual Science; Journal of Neurochemistry; Journal of Ophthalmology; Journal of Pathology; Molecular Vision; Nutrients.

#### **Ad hoc reviewer for granting agencies**

MIUR

French Ministry of Health

National Cancer Institute of France

National Science Center Poland.

#### **Affiliation to Scientific Societies**

Italian Physiological Society (SIF)

European Association for Vision and Eye Research (EVER)

European Association for the Study of Diabetes (EASD)

#### **Research Grants**

**2023:** Research grant from Ministry of University and Research (PRIN 2022), Italy

**2022:** Research grant from Ministry of University and Research (PNRR – National Centres), Italy

**2022:** Research grant from Ministry of University and Research (PNRR – Innovation Ecosystems), Italy

**2022:** Research grant from Italian Spatial Agency, Italy

**2022:** Research grant from Kemin Industries, USA

**2022:** Research grant from University of Naples, Italy

**2022:** Research grant from Chiesi Farmaceutici, Italy

**2020:** Research grant from Azienda Ospedaliero-Universitaria Meyer, Italy.

**2020:** Research grant from Sooft Italia SpA, Italy.

**2018-present:** Research grant from the University of Pisa, Italy.

**2018-2019:** Research grant from Sooft Italia SpA, Italy.

**2016-2017:** Research grant from Indena SpA, Italy.

**2015-2016:** Research grant from the University of Pisa, Italy.

**2013-2014:** Research grant from Ospedale Pediatrico Meyer, Italy.

**2011-2013:** Research grant from The International Retina Research Foundation, USA.

**2011-2012:** Research grant from Fondazione Meyer, Italy.

**2009-2011:** Research grant from The International Retina Research Foundation, USA.

**2008-2010:** Research grant from the University of Pisa, Italy.

**2007-2008:** Research grant from Fondazione Cassa di Risparmio di Volterra, Italy.

**2006-present:** Annual support from the University of Pisa, Italy.

#### **Invited talks**

**2023:**

**2018:** Beta3-adrenoceptors as drug targets in melanoma. 10<sup>th</sup> Adrenoceptor Symposium. Shizuoka; Japan; June 28<sup>th</sup>-30<sup>th</sup>.

**2017** Anti-angiogenic and anti-inflammatory role of boswellic acids. Workshop “Progetto IDARA - Alimenti funzionali: un valido ausilio nel controllo della patologia diabetica e dei processi infiammatori”. Pisa; June 22<sup>nd</sup>.

**2017:** Effect of Macular FAG in a murine model of macular degeneration. Third International Congress Vitreo-Retina Forever; Acquaviva delle Fonti (BA); January 12<sup>th</sup>-14<sup>th</sup>.

**2016:** The beta-adrenergic system as a possible new target for pharmacological treatment of neovascular retinal diseases. Symposium "Old drugs-new uses: novel therapies targeting the beta adrenergic system". Sixty-seventh Annual Meeting of the Physiological Society of Italy; Catania; September 21<sup>st</sup>-23<sup>rd</sup>.

**2015:** Treating proliferative retinopathies: from laser photocoagulation to anti-VEGF drugs and beyond. SIICA Workshop "Angiogenesi: basi molecolari ed implicazioni terapeutiche V"; Certosa di Pontignano (SI); May 25<sup>th</sup>-27<sup>th</sup>.

**2013:** Role of beta adrenergic system in retinal angiogenesis. SIICA Workshop "Angiogenesi: basi molecolari ed implicazioni terapeutiche IV"; Certosa di Pontignano (SI); May 13<sup>rd</sup>-15<sup>th</sup>.

**2012:** Neuroprotective factors against retinal injury in response to hypoxia: new perspectives. Symposium "Neuronal death processes in retinal disease"; European Association for Vision and Eye Research Congress 2012; Nice, France; October 10<sup>th</sup>-13<sup>th</sup>.

**2010:** Retinal neovascularisation and its implication in retinal dysfunctions. Symposium "Cerebral blood flow and neuronal functions: from physiology to animal models of vascular pathology"; Sixty-first Annual Meeting of the Physiological Society of Italy; Varese; September 15<sup>th</sup>-17<sup>th</sup>.

### **Publications of the last 5 years**

1. Scaramuzza R.T.; Bagnoli P.; **Dal Monte M.**; Cammalleri M.; Pini A.; Ballini S.; Bendinelli A.; Desideri I; Ciantelli M.; Filippi L. (2023). "Treating infants with 0.2% propranolol eye micro-drops drastically reduced the progression of retinopathy of prematurity". *Acta Paediatr.* doi: 10.1111/apa.16850
2. Cammalleri M.; Amato R.; **Dal Monte M.**; Filippi L.; Bagnoli P. (2023). "The  $\beta_3$  adrenoceptor in proliferative retinopathies: "Cinderella" steps out of its family shadow". *Pharmacol. Res.*, 190:106713.
3. Cantarini M.; Rusciano D.; Amato R.; Canovai A.; Cammalleri M.; **Dal Monte M.**; Minnelli C.; Laudadio E.; Mobbili G.; Giorgini G.; Galeazzi R. (2023). "Structural basis for agonistic activity and selectivity toward melatonin receptors hMT1 and hMT2". *Int. J. Mol. Sci.* 24:2863.
4. Amato R.; Catalani E.; **Dal Monte M.**; Cammalleri M.; Cervia D.; Casini G. (2022). "Morpho-functional analysis of the early changes induced in retinal ganglion cells by the onset of diabetic retinopathy: the effects of a neuroprotective strategy". *Pharmacol. Res.*, 185:106516.
5. Melecchi A.; Amato R.; Lapi D.; **Dal Monte M.**; Rusciano D.; Bagnoli P.; Cammalleri M. (2022). "Increased efficacy of dietary supplement containing wax ester-rich marine oil and xanthophylls in a mouse model of dry macular degeneration". *Front. Pharmacol.*, 13:1038730.
6. Koskela A.; Manai F.; Basagni F.; Liukkonen M.; Rosini M.; Govoni S.; Dal Monte M.; Smedowski A.; Kaarniranta K.; Amadio M. (2022). "Nature-Inspired Hybrids (NIH) Improve Proteostasis by Activating Nrf2-Mediated Protective Pathways in Retinal Pigment Epithelial Cells". *Antioxidants*, 11:1385.
7. Lucchesi M.; Marracci S.; Amato R.; Filippi L.; Cammalleri M.; **Dal Monte M.** (2022). "Neurosensory alterations in retinopathy of prematurity: a window to neurological impairments associated to preterm birth". *Biomedicines*, 10:1603.
8. Amato R.; Pisani F.; Laudadio E.; Lucchesi M.; Marracci S.; Cammalleri M.; Filippi L.; Galeazzi R.; Svelto M.; **Dal Monte M.**; Bagnoli P. (2022). "HIF-1-dependent induction of  $\beta_3$ -adrenoceptor: evidence from the mouse retina". *Cells.*, 11:1271.
9. Filippi L.; Pini A.; Cammalleri M.; Bagnoli P.; **Dal Monte M.** (2022). " $\beta_3$ -adrenoceptor, a novel player in the round-trip from neonatal diseases to cancer: suggestive clues from embryo". *Med. Res. Rev.*, 42:1179-1201.
10. Filippi L.; Cammalleri M.; Amato R.; Ciantelli M.; Pini A.; Bagnoli P.; **Dal Monte M.** (2022). "Decoupling oxygen tension from retinal vascularization as a new perspective for management of Retinopathy of Prematurity. Current opportunities and futuristic scenarios". *Front. Pharmacol.*, 13:835771.

11. Canovai A.; Amato R.; Melecchi, A.; **Dal Monte M.**; Rusciano D.; Bagnoli P.; Cammalleri M. (2022). “Preventive efficacy of antioxidant compounds on blood retinal barrier breakdown and visual dysfunction in streptozotocin-induced diabetic rats”. *Front. Pharmacol.*, 12:811818.
12. Lapi D.; Cammalleri M.; **Dal Monte M.**; Di Maro M.; Santillo M.R.; Belfiore A.; Nasti G.; Damiano S.; Trio R.; Chiurazzi M.; De Conno B.; Serao N.; Mondola P.; Colantuoni A.; Guida B. (2021). “The effects of Angiotensin II or Angiotensin 1-7 on rat pial microcirculation during hypoperfusion and reperfusion injury: role of redox stress”. *Biomolecules.*, 11:1861.
13. Morrone D.; Picoi M.E.L.; Felice F.; De Martino A.; Scatena C.; Spontoni P.; Naccarato G.; Di Stefano R.; Bortolotti U.; **Dal Monte M.**; Pini S.; Abelli M.; Balbarini A. (2021). “Endothelial progenitor cells. An appraisal of relevant data from bench to bedside”. *Int. J. Mol. Sci.*, 22:12874.
14. Pesce N.A.; Canovai A.; Plastino F.; Lardner E.; Kvanta A.; Cammalleri M.; André H.; **Dal Monte M.** (2021). “An imbalance in autophagy contributes to retinal damage in a rat model of oxygen-induced retinopathy”. *J. Cell. Mol. Med.*, 25:10480-10493.
15. Amato R.; Canovai A.; Melecchi A.; Pezzino S.; Corsaro R.; **Dal Monte M.**; Rusciano D.; Bagnoli P.; Cammalleri M. (2021). “Dietary supplementation of antioxidant compounds prevents light-induced retinal damage in a rat model”. *Biomedicines*, 9:1177.
16. Rossino M.G.; Amato R.; Amadio M.; Rosini M.; Basagni F.; Cammalleri M.; **Dal Monte M.**; Casini G. (2021). “A nature-inspired Nrf2 activator protects retinal explants from oxidative stress and neurodegeneration”. *Antioxidants*, 10:1296.
17. Milano S.; Carosino M.; Gerbino A.; Saponara I.; **Dal Monte M.**; Bagnoli P.; Svelto M.; Procino G. (2021). “Activation of the thiazide-sensitive sodium-chloride cotransporter NCC by beta3-adrenoreceptor in the distal convolute tubule”. *Front. Physiol.*, 12:695824
18. Amato R.; Rossino M.G.; Cammalleri M.; Timperio A.M.; Fanelli G.; **Dal Monte M.**; Pucci L.; Casini G. (2021). “The potential of Lisosan G as a possible treatment for glaucoma”. *Front. Pharmacol.*, 12:719951.
19. Amato R.; Lazzara F.; Chou T.H.; Romano G.; Cammalleri M., **Dal Monte M.**; Casini G.; Porciatti V. (2021). “Diabetes exacerbates the intraocular pressure-independent retinal ganglion cells degeneration in the DBA/2J model of glaucoma”. *Invest. Ophthalmol. Vis. Sci.*, 62:9.
20. Cammalleri M.; Amato R.; Olivieri M.; Pezzino S.; Bagnoli P.; **Dal Monte M.**; Rusciano D. (2021). “Effects of Topical Gabapentin on Ocular Pain and Tear Secretion”. *Front. Pharmacol.*, 12:671238.
21. Pesce N.A.; Canovai A.; Lardner E.; Cammalleri M.; Kvanta A.; André H.; **Dal Monte M.** (2021). “Autophagy Involvement in the Postnatal Development of the Rat Retina”. *Cells*, 10:177.
22. **Dal Monte M.**; Cammalleri M.; Amato R.; Pezzino S.; Corsaro R.; Bagnoli P.; Rusciano D. (2020). “A Topical Formulation of Melatonergic Compounds Exerts Strong Hypotensive and Neuroprotective Effects in a Rat Model of Hypertensive Glaucoma”. *Int. J. Mol. Sci.*, 21:9267.
23. Filippi L.; **Dal Monte M.** (2020). “A safety review of drugs used for the treatment of retinopathy of prematurity”. *Expert Opin. Drug Saf.*, 19:1409-1418.
24. Locri F.; Pesce N.A.; Aronsson M.; Cammalleri M.; De Rosa M.; Pavone V.; Bagnoli P.; Kvanta A.; **Dal Monte M.**; André H. (2020). “Gaining insight on mitigation of rubeosis iridis by UPARANT in a mouse model associated with proliferative retinopathy”. *J. Mol. Med.*, 98:1629-1638.
25. Cammalleri M.; **Dal Monte M.**; Amato R.; Lapi D.; Bagnoli P. (2020). “Novel insights into beta 2 adrenergic receptor function in the rd10 model of retinitis pigmentosa”. *Cells*, 9:2060.
26. Rossino M.G.; Lulli M.; Amato R.; Cammalleri M.; **Dal Monte M.**; Casini G. (2020). “Oxidative stress induces a VEGF autocrine loop in the retina: relevance for diabetic retinopathy”. *Cells*, 9:1452.

27. Cammalleri M.; **Dal Monte M.**; Amato R.; Bagnoli P.; Rusciano D. (2020). “A dietary combination of forskolin with homotaurine, spearmint and B vitamins protects injured retinal ganglion cells in a rodent model of hypertensive glaucoma”. *Nutrients*, 12:1189.
28. **Dal Monte M.**; Cammalleri M.; Pezzino S.; Corsaro R.; Pescosolido N.; Bagnoli P.; Rusciano D. (2020). “Hypotensive Effect of Nanomicellar Formulation of Melatonin and Agomelatine in a Rat Model: Significance for Glaucoma Therapy”. *Diagnostics (Basel)*, 10: E138.
29. **Dal Monte M.**; Tavanti A.; Poma N.; Rusciano D. (2020). “Dexamethasone Improves Ofloxacin Efficacy in Treating Acute Bacterial Conjunctivitis: Evidence from A Rabbit Model.” *Biomed. J. Sci.Tech. Res.* 26: 19598-19605.
30. Amato R.; Giannaccini M.; **Dal Monte M.**; Cammalleri M.; Pini A.; Raffa V.; Lulli M.; Casini G. (2020). “Association of the somatostatin analog octreotide with magnetic nanoparticles for intraocular delivery: a possible approach for the treatment of diabetic retinopathy”. *Front. Bioeng. Biotechnol.*, 8: 144.
31. **Dal Monte M.**; Evans B.; Arioglu-Inan E.; Michel M.C. (2020). “Upregulation of  $\beta_3$ -adrenergic receptors – a general marker of and protective mechanism against hypoxia?”. *Naunyn Schmiedebergs Arch. Pharmacol.*, 393: 141-146.
32. Locri F.; Cammalleri M.; **Dal Monte M.**; Rusciano D.; Bagnoli P. (2019). “Protective efficacy of a dietary supplement based on forskolin, homotaurine, spearmint extract and group B vitamins in a mouse model of optic nerve injury”. *Nutrients*, 11:2931.
33. Filippi L.; Cavallaro G.; Perciasepe L.; Sandini E.; Araimo G.; Regiroli G.; Raffaelli G.; Bagnoli P.; **Dal Monte M.**; Calvani M.; Fortunato P.; Osnaghi S.; Mosca F. (2019). “Refractive outcome in preterm newborns with ROP after propranolol treatment. A retrospective observational cohort study”. *Front. Pediatr.*, 7:479.
34. Rossino M.G.; **Dal Monte M.**; Casini G. (2019). “Relationships between neurodegeneration and vascular damage in diabetic retinopathy”. *Front. Neurosci.*, 13:1172.
35. Locri F.; **Dal Monte M.**; Aronsson M.; Cammalleri M.; De Rosa M.; Pavone V.; Kvant A.; Bagnoli P.; André H. (2019). “UPARANT is an effective antiangiogenic agent in a mouse model of rubeosis iridis”. *J. Mol. Med.*;23:5176-5192.
36. Bagnoli P.; Cammalleri M.; **Dal Monte M.**; Rusciano D.; De Rosa M.; Pavone V. (2019). “The uPAR system as a potential therapeutic target in the diseased eye”. *Cells*; 8:925.
37. Cammalleri M.; **Dal Monte M.**; Locri F.; Pecci V.; De Rosa M.; Pavone V.; Bagnoli P. (2019). “The urokinase-type plasminogen activator system as drug target in retinitis pigmentosa: new pre-clinical evidence in the rd10 mouse model”. *J. Cell. Mol. Med.* 23:5176-5192.
38. Calvani M.; Bruno G.; **Dal Monte M.**; Nassini R.; Fontani F.; Casini A.; Cavallini L.; Becatti M.; Bianchini F.; De Logu F.; Forni G.; la Marca G.; Calorini L.; Bagnoli P.; Chiarugi P.; Pupi A.; Azzari C.; Geppetti P.; Favre C.; Filippi L. (2019). “ $\beta_3$ -adrenoceptor as a potential immunosuppressor agent in melanoma”. *Br. J. Pharmacol.*; 176:2509-2524.
39. **Dal Monte M.**; Calvani M.; Cammalleri M.; Favre C.; Filippi L.; Bagnoli P. (2019). “ $\beta_3$ -adrenoceptors as drug targets in melanoma: novel preclinical evidence for a role of  $\beta_3$ -adrenoceptors”. *Br. J. Pharmacol.*; 176:2496-2508.
40. Filippi L.; Cavallaro G.; Berti E.; Padrini L.; Araimo G.; Regiroli G.; Raffaelli G.; Bozzetti V.; Tagliabue P.; Tomasini B.; Mori A.; Buonocore G.; Agosti M.; Bossi A.; Chirico G.; Aversa S.; Fortunato P.; Osnaghi S.; Cavallotti B.; Susani M.; Vanni M.; Borsari G.; Donati S.; Nascimbeni G.; Nardo D.; Piermarocchi S.; la Marca G.; Forni G.; Milani S.; Cortinovis I.; Calvani M.; Bagnoli P.; **Dal Monte M.**; Calvani A.M.; Pugi A.; Villamor E.; Donzelli G.; Mosca F. (2019). “Propranolol 0.2% eye micro-drops for Retinopathy of Prematurity: a prospective phase IIB study”. *Front. Pediatr.*; 7:180.
41. **Dal Monte M.**; Cammalleri M.; Pecci V.; Carmosino M.; Procino G.; De Rosa M.; Pavone V.; Svelto M.; Bagnoli P. (2019). “Inhibiting the urokinase-type plasminogen activator receptor system recovers STZ-induced diabetic nephropathy”. *J. Cell. Mol. Med.*; 23:1034-1049.

42. Amato R.; Rossino M.G.; Cammalleri M.; Locri F.; Pucci L.; **Dal Monte M.**; Casini G. (2018). "Lisosan G Protects the Retina from Neurovascular Damage in Experimental Diabetic Retinopathy". *Nutrients*; 10:1932.
43. Calvani M.; Cavallini L.; Tondo A.; Spinelli V.; Ricci L.; Pasha A.; Bruno G.; Buonvicino D.; Bigagli E.; Vignoli M.; Bianchini F.; Sartiani L.; Lodovici M.; Semeraro R.; Fontani F.; De Logu F.; **Dal Monte M.**; Chiarugi P.; Favre C.; Filippi L. (2018). "β3-adrenoreceptors control mitochondrial dormancy in melanoma and embryonic stem cells". *Oxid. Med. Cell. Longev.*; 2018:6816508.
44. Locri F.; Cammalleri M.; Pini A.; **Dal Monte M.**; Rusciano D.; Bagnoli P. (2018). "Further evidence on efficacy of diet supplementation with fatty acids in ocular pathologies: insights from the EAE model of optic neuritis". *Nutrients*; 10:1447.
45. Amato R.; **Dal Monte M.**; Lulli M.; Raffa V.; Casini G. (2018). "Nanoparticle-Mediated Delivery of Neuroprotective Substances for the Treatment of Diabetic Retinopathy". *Curr. Neuropharmacol.*; 16:993-1003.
46. **Dal Monte M.**; Cammalleri M.; Locri F.; Amato R.; Marsili S.; Rusciano D.; Bagnoli P. (2018). "Fatty acids dietary supplements exert anti-inflammatory action and limit ganglion cell degeneration in the retina of the EAE mouse model of multiple sclerosis". *Nutrients*; 10:325.
47. Amato R.; Catalani E.; **Dal Monte M.**; Cammalleri M.; Di Renzo I.; Perrotta C.; Cervia D.; Casini G. (2018). "Autophagy-mediated neuroprotection induced by octreotide in an ex vivo model of early diabetic retinopathy". *Pharmacol. Res.*; 128:167-178.
48. Pisani F.; Cammalleri M.; **Dal Monte M.**; Locri F.; Mola M.G.; Nicchia G.P.; Frigeri A.; Bagnoli P.; Svelto M. (2018). "Potential role of the methylation of VEGF gene promoter in response to hypoxia in oxygen-induced retinopathy: beneficial effect of the absence of AQP4". *J. Cell. Mol. Med.*; 22:613-627.

### **Book chapters**

1. **Dal Monte M.** (2019) "Capitolo 7 – Sistema nervoso: organizzazione anatomica". *In* Taglietti V. (Ed.) "Fondamenti di Fisiologia generale e integrata". pp. 164-188. EdiSES, Napoli.
2. **Dal Monte M.** (2019) "Capitolo 8 – Sistema nervoso: sistemi motorio, sensoriale, autonomo e funzioni nervose superiori" (with the exception of the part dedicated to the sensory system). *In* Taglietti V. (Ed.) "Fondamenti di Fisiologia generale e integrata". pp. 189-204; 271-291. EdiSES, Napoli.
3. Filippi L.; Cammalleri M.; **Dal Monte M.** (2015) "Targeting the Beta-Adrenergic System to Treat retinopathy of Prematurity: A New Therapeutic Approach?". *In* Aguilar E. (Ed) "Retinopathy of Prematurity (ROP). Classification; Risk Factors and Treatment". pp 1-34. Nova Science Publisher; New York.
4. **Dal Monte M.** (2011) "Modelli animali di patologie oculari". *In* Carella G.; Cerulli L.; Simonetti G. (Eds) "La via ottica dalle origini alla contemporaneità". pp 413-423. Edizioni SOI.

### **Patents**

1. Svelto M.; Procino G.; Carmosino M.; **Dal Monte M.**; Bagnoli P. (2014). "Agonisti selettivi dei recettori beta-adrenergici di tipo 3 (BAR3) e loro impiego". MI2014A001676. International patent.
2. Filippi L.; Bilia A.R.; Isacchi B.; la Marca G.; Bagnoli P.; **Dal Monte M.**; Fiorini P.; Ristori C. (2014). "Sistemi oftalmici per il rilascio di farmaci al segmento posteriore dell'occhio per la somministrazione oculare di beta-2-bloccanti per l'uso nel trattamento di retinopatie proliferative". FI2014A000061. National patent.
3. Capaccioli S.; Lulli M.; **Dal Monte M.** (2010). "Uso di oligonucleotidi antisenso per il trattamento di degenerazioni e neoplasie retiniche". MI20101030. National patent.

### **Bibliometric indices**

**Google Scholar (July 31, 2023)**

Citations: 3812

h index: 37

**Scopus (July 31, 2023)**


Citations: 2943

h index: 33

**WOS (July 31, 2023)**

Citations: 2791

h index: 32

A handwritten signature in black ink, appearing to be 'Rajiv' with a long horizontal stroke extending to the right.